Immix Biopharma Inc (IMMX)

$4.94 -0.16 (-3.14%)
Market Cap 182.33M
Revenue (ttm) 0.00
Net Income (ttm) -21.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 824,142
Avg Vol 1,028,472
Day's Range N/A - N/A
Shares Out 33.58M
Stochastic %K 7%
Beta 0.31
Analysts Sell
Price Target $12.00

Company Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was in...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 651 8041
Address:
11400 West Olympic Boulevard, Suite 200, Los Angeles, United States
Anastasis21
Anastasis21 Jan. 6 at 9:10 PM
$IMMX how much more??? when the free falling will stop?
0 · Reply
Georggggie
Georggggie Jan. 6 at 7:23 PM
$IMMX
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 6 at 6:10 PM
Enter: $IMMX Calls Strike Price: $8 Expiry Date: FEB 20 2026 Buy in Price: $0.85 - $4.50 Sell Price: $1.67 Profit : +96% (Turn every $1 into $1.96) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Monica69
Monica69 Jan. 6 at 5:28 PM
$IMMX
0 · Reply
LatinResearch
LatinResearch Jan. 6 at 4:52 PM
$IMMX A big player brought SP down and will keep it there for some reason for as long as need it for them. IMO There are ongoing negotiations that are much better for Big Pharma at $5 than $15, where the SP should be now. Nothing we can do but hold and wait. The good news is that if there was some bad news SP would be <$1 already.
0 · Reply
Tunes444
Tunes444 Jan. 6 at 3:37 PM
$IMMX was gunna say the same thing lol $100M to get this done is a crazy dollar figure
0 · Reply
ASTB14
ASTB14 Jan. 6 at 3:35 PM
$IMMX Raising $100M shows the credibility behind the science... niche need, but one IMMX gets 100% of the upside!
0 · Reply
Guptasulo
Guptasulo Jan. 6 at 2:22 PM
$INKT $IMMX $SNSE INKT; Activity seen where chemo has failed. Responses reported across multiple tumor types (Ph1) Pattern suggests potential platform oncology drug (not single-indication) Platform level; multiple cancer treatments. Ph2 interim expected Jan 2026. Micro-float (~5M OS) and ~$60M market cap.
0 · Reply
TheHookingBull
TheHookingBull Jan. 6 at 4:41 AM
$IMMX anyone getting margin trading on immx? If so, by how much? Not marginable on Webull.
0 · Reply
RiccoTheGreat2
RiccoTheGreat2 Jan. 6 at 12:34 AM
$IMMX Well fuck!
0 · Reply
Latest News on IMMX
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition

Dec 11, 2025, 12:10 AM EST - 26 days ago

Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Dec 9, 2025, 5:45 PM EST - 27 days ago

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Dec 7, 2025, 6:20 PM EST - 4 weeks ago

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Dec 7, 2025, 6:15 PM EST - 4 weeks ago

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

Nov 12, 2025, 8:45 AM EST - 7 weeks ago

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'

Nov 6, 2025, 2:39 PM EST - 2 months ago

Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Nov 3, 2025, 8:45 AM EST - 2 months ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 14, 2025, 8:45 AM EDT - 3 months ago

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

Oct 6, 2025, 4:05 PM EDT - 3 months ago

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

Oct 1, 2025, 8:45 AM EDT - 3 months ago

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

Sep 18, 2025, 1:30 PM EDT - 3 months ago

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

Sep 11, 2025, 9:15 AM EDT - 4 months ago

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

Sep 8, 2025, 4:05 PM EDT - 4 months ago

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

Aug 25, 2025, 9:30 AM EDT - 4 months ago

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

Immix Biopharma Announces Other Serious Diseases Strategy

Aug 6, 2025, 12:30 PM EDT - 5 months ago

Immix Biopharma Announces Other Serious Diseases Strategy

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

Jul 11, 2025, 9:36 AM EDT - 6 months ago

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Jul 7, 2025, 9:35 AM EDT - 6 months ago

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Immix Biopharma Attends FDA CEO Forum in Washington DC

Jun 6, 2025, 9:39 AM EDT - 7 months ago

Immix Biopharma Attends FDA CEO Forum in Washington DC

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Jun 3, 2025, 2:55 PM EDT - 7 months ago

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

May 23, 2025, 9:05 AM EDT - 8 months ago

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

May 22, 2025, 4:02 PM EDT - 8 months ago

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

May 21, 2025, 4:03 PM EDT - 8 months ago

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

Apr 23, 2025, 10:04 AM EDT - 9 months ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Feb 10, 2025, 9:35 AM EST - 11 months ago

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

Jan 7, 2025, 9:34 AM EST - 1 year ago

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

Dec 19, 2024, 9:35 AM EST - 1 year ago

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

Dec 16, 2024, 9:48 AM EST - 1 year ago

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Dec 10, 2024, 9:39 AM EST - 1 year ago

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

Dec 9, 2024, 9:33 AM EST - 1 year ago

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Nov 25, 2024, 9:32 AM EST - 1 year ago

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Oct 2, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

Sep 19, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Aug 28, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Jul 25, 2024, 9:36 PM EDT - 1 year ago

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Jul 8, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

Jun 17, 2024, 9:35 AM EDT - 1 year ago

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

May 10, 2024, 9:35 AM EDT - 1 year ago

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Apr 29, 2024, 9:39 AM EDT - 1 year ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Apr 18, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Apr 15, 2024, 9:36 AM EDT - 1 year ago

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Mar 20, 2024, 9:46 AM EDT - 1 year ago

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Mar 5, 2024, 9:35 AM EST - 2 years ago

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Immix Biopharma 12 Month Review Progress Update

Feb 21, 2024, 9:31 AM EST - 2 years ago

Immix Biopharma 12 Month Review Progress Update

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Feb 8, 2024, 4:45 PM EST - 2 years ago

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

Feb 7, 2024, 9:37 AM EST - 2 years ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Feb 5, 2024, 10:30 PM EST - 2 years ago

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Immix Biopharma Announces Proposed Public Offering of Common Stock

Feb 5, 2024, 3:20 PM EST - 2 years ago

Immix Biopharma Announces Proposed Public Offering of Common Stock

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

Jan 24, 2024, 8:35 AM EST - 2 years ago

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

Dec 18, 2023, 9:39 AM EST - 2 years ago

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

Dec 11, 2023, 9:36 AM EST - 2 years ago

Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

Anastasis21
Anastasis21 Jan. 6 at 9:10 PM
$IMMX how much more??? when the free falling will stop?
0 · Reply
Georggggie
Georggggie Jan. 6 at 7:23 PM
$IMMX
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 6 at 6:10 PM
Enter: $IMMX Calls Strike Price: $8 Expiry Date: FEB 20 2026 Buy in Price: $0.85 - $4.50 Sell Price: $1.67 Profit : +96% (Turn every $1 into $1.96) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Monica69
Monica69 Jan. 6 at 5:28 PM
$IMMX
0 · Reply
LatinResearch
LatinResearch Jan. 6 at 4:52 PM
$IMMX A big player brought SP down and will keep it there for some reason for as long as need it for them. IMO There are ongoing negotiations that are much better for Big Pharma at $5 than $15, where the SP should be now. Nothing we can do but hold and wait. The good news is that if there was some bad news SP would be <$1 already.
0 · Reply
Tunes444
Tunes444 Jan. 6 at 3:37 PM
$IMMX was gunna say the same thing lol $100M to get this done is a crazy dollar figure
0 · Reply
ASTB14
ASTB14 Jan. 6 at 3:35 PM
$IMMX Raising $100M shows the credibility behind the science... niche need, but one IMMX gets 100% of the upside!
0 · Reply
Guptasulo
Guptasulo Jan. 6 at 2:22 PM
$INKT $IMMX $SNSE INKT; Activity seen where chemo has failed. Responses reported across multiple tumor types (Ph1) Pattern suggests potential platform oncology drug (not single-indication) Platform level; multiple cancer treatments. Ph2 interim expected Jan 2026. Micro-float (~5M OS) and ~$60M market cap.
0 · Reply
TheHookingBull
TheHookingBull Jan. 6 at 4:41 AM
$IMMX anyone getting margin trading on immx? If so, by how much? Not marginable on Webull.
0 · Reply
RiccoTheGreat2
RiccoTheGreat2 Jan. 6 at 12:34 AM
$IMMX Well fuck!
0 · Reply
osamabinrussell
osamabinrussell Jan. 5 at 8:31 PM
$IMMX 1
0 · Reply
WhyMeWorry
WhyMeWorry Jan. 5 at 8:10 PM
$IMMX
0 · Reply
CoralC
CoralC Jan. 5 at 7:22 PM
$IMMX
0 · Reply
dudududucharles
dudududucharles Jan. 5 at 6:32 PM
$IMMX they were making a lot of promising progress as they closed out last year. No doubt in my mind they can carry that over now
0 · Reply
Tunes444
Tunes444 Jan. 5 at 5:11 PM
$IMMX
0 · Reply
bnglao24
bnglao24 Jan. 5 at 2:22 PM
$IMMX Autoimmune Proof of Concept Data Importance: The SSc and IIM data open a Total Addressable Market (TAM) 5-10x LARGER than AL Amyloidosis. The ability to reverse fibrosis (SSc) suggests NXC-201 is not just an immunosuppressant but a disease-modifying regenerative therapy. Patiently waiting for them to PR a better defined autoimmune strategy and hopefully management is at least engaged with FDA on designation for SSc. Seems like a no-brainer after the last raise and the best way to drive value for the stock. Big pharma cares less about single indication asset and more about multi-indication platforms. Just the fact
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 5 at 12:03 AM
Enter: $IMMX Calls Strike Price: $8 Expiry Date: FEB 20 2026 Buy in Price: $0.85 - $1.05 Sell Price: $1.29 Profit : +52% (Turn every $1 into $1.52) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Stocks4Sophia
Stocks4Sophia Jan. 4 at 7:22 AM
$IMMX
0 · Reply
Nolder
Nolder Jan. 3 at 7:22 PM
$IMMX
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 3 at 6:55 PM
Enter: $IMMX Calls Strike Price: $8 Expiry Date: FEB 20 2026 Buy in Price: $0.85 - $1.05 Sell Price: $1.70 Profit : +100% (Turn every $1 into $2.00) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/pricing
0 · Reply
bnglao24
bnglao24 Jan. 3 at 1:21 PM
$IMMX Not necessarily new but coverage from a reputable oncology publication https://www.cancernetwork.com/view/nxc-201-yields-rapid-responses-in-small-r-r-al-amyloidosis-cohort#:~:text=December%208%2C%202025-,NXC%2D201%20Yields%20Rapid%20Responses%20in,R%2FR%20AL%20Amyloidosis%20Cohort&text=More%20than%20half%20of%20evaluable,following%20treatment%20with%20NXC%2D201.
0 · Reply
IndyJones67
IndyJones67 Jan. 3 at 7:22 AM
$IMMX
0 · Reply